Literature DB >> 23473980

Antiangiogenic effects of melatonin in endothelial cell cultures.

Virginia Alvarez-García1, Alicia González, Carolina Alonso-González, Carlos Martínez-Campa, Samuel Cos.   

Abstract

Endothelial cells represent one of the critical cellular elements in tumor microenvironment playing a crucial role in the growth and progression of cancer through controlling angiogenesis. Vascular endothelial growth factor (VEGF) produced from tumor cells is essential for the expansion of breast cancer and may function in both paracrine and autocrine manners to promote proliferation, growth, survival and migration of endothelial cells. Since melatonin regulates tumor microenvironment by decreasing the secretion of VEGF by malignant epithelial cells and also regulates VEGF expression in human breast cancer cells, the aim of the present study was to investigate the anti-angiogenic activity of melatonin against the pro-angiogenic effects of breast cancer cells. In this work, we demonstrate that melatonin strongly inhibited the proliferation as well as invasion/migration of human umbilical vein endothelial cells (HUVECs). Melatonin disrupted tube formation and counteracted the VEGF-stimulated tubular network formation by HUVEC. In addition, conditioned media collected from human breast cancer cells were angiogenically active and stimulated tubule length formation and this effect was significantly counteracted by the addition of anti-VEGF or melatonin. Melatonin also disintegrated preformed capillary network. All these findings demonstrate that melatonin may play a role in the paracrine interactions that take place between malignant epithelial cells and proximal endothelial cells. Melatonin could be important in reducing endothelial cell proliferation, invasion, migration and tube formation, through a downregulatory action on VEGF. Taken together, our findings suggest that melatonin could potentially be beneficial as an antiangiogenic agent in breast cancer with possible future clinical applications.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23473980     DOI: 10.1016/j.mvr.2013.02.008

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  25 in total

1.  Melatonin represses oral squamous cell carcinoma metastasis by inhibiting tumor-associated neutrophils.

Authors:  Haibin Lu; Baolei Wu; Ge Ma; Deyu Zheng; Ruijuan Song; Erjiang Huang; Ming Mao; Bin Lu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

Review 2.  Melatonin and ubiquitin: what's the connection?

Authors:  Jerry Vriend; Russel J Reiter
Journal:  Cell Mol Life Sci       Date:  2014-06-12       Impact factor: 9.261

3.  Melatonin exerts anti-angiogenic and anti-inflammatory effects in alkali-burned corneas.

Authors:  Jie Meng; Bingying Lin; Siyu Huang; Yangyang Li; Pengsen Wu; Fan Zhang; Yu Ke; Xiangqing Hei; Danping Huang
Journal:  Ann Transl Med       Date:  2022-04

4.  Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer.

Authors:  Bruna Victorasso Jardim-Perassi; Ali S Arbab; Lívia Carvalho Ferreira; Thaiz Ferraz Borin; Nadimpalli R S Varma; A S M Iskander; Adarsh Shankar; Meser M Ali; Debora Aparecida Pires de Campos Zuccari
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

5.  Melatonin suppresses hypoxia-induced migration of HUVECs via inhibition of ERK/Rac1 activation.

Authors:  Ling Yang; Jianchao Zheng; Rui Xu; Yujie Zhang; Luo Gu; Jing Dong; Yichao Zhu; Ruijue Zhou; Lu Zheng; Xiaoying Zhang; Jun Du
Journal:  Int J Mol Sci       Date:  2014-08-13       Impact factor: 5.923

Review 6.  Broad targeting of angiogenesis for cancer prevention and therapy.

Authors:  Zongwei Wang; Charlotta Dabrosin; Xin Yin; Mark M Fuster; Alexandra Arreola; W Kimryn Rathmell; Daniele Generali; Ganji P Nagaraju; Bassel El-Rayes; Domenico Ribatti; Yi Charlie Chen; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Somaira Nowsheen; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; Bill Helferich; Xujuan Yang; Gunjan Guha; Dipita Bhakta; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Dorota Halicka; Sulma I Mohammed; Asfar S Azmi; Alan Bilsland; W Nicol Keith; Lasse D Jensen
Journal:  Semin Cancer Biol       Date:  2015-01-16       Impact factor: 15.707

7.  The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.

Authors:  Richard E Kast; Nicolas Skuli; Samuel Cos; Georg Karpel-Massler; Yusuke Shiozawa; Ran Goshen; Marc-Eric Halatsch
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-07-11

8.  Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells.

Authors:  S Carbajo-Pescador; R Ordoñez; M Benet; R Jover; A García-Palomo; J L Mauriz; J González-Gallego
Journal:  Br J Cancer       Date:  2013-06-11       Impact factor: 7.640

9.  Melatonin modulation of crosstalk among malignant epithelial, endothelial and adipose cells in breast cancer (Review).

Authors:  Samuel Cos; Virginia Alvarez-García; Alicia González; Carolina Alonso-González; Carlos Martínez-Campa
Journal:  Oncol Lett       Date:  2014-05-30       Impact factor: 2.967

10.  Propionibacterium acnes Augments Antitumor, Anti-Angiogenesis and Immunomodulatory Effects of Melatonin on Breast Cancer Implanted in Mice.

Authors:  Wamidh H Talib; Suhair Saleh
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.